文献速递肝病消化道肿瘤与早癌

肝细胞癌降低直接抗病毒药物治疗丙型肝炎病毒成功的机会

Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
PubMed 文献 · J Hepatol · 2017-02-02

该回顾性队列研究纳入2014年1月至2015年11月在本机构接受全口服直接抗病毒药物(DAA)治疗的421例丙型肝炎病毒(HCV)阳性肝硬化患者,33%有活动性或既往肝细胞癌(HCC)。HCC患者未获得持续病毒学应答(SVR)的比例为21%,无HCC患者为12%(p=0.009)。多变量分析显示,HCV治疗开始时存在活动性HCC是DAA治疗失败的主要预测因素(调整OR=8.5,95%CI=3.90-18.49)。

要点

  • HCV阳性肝硬化患者中,HCC患者DAA治疗失败率21%,无HCC患者12%(p=0.009)。
  • 29例未获得SVR的HCC患者中,27例(93%)发生在存在活动性肿瘤时。
  • 活动性HCC是DAA治疗失败的主要预测因素(调整OR=8.5,95%CI=3.90-18.49)。

核心结论

  • HCV治疗开始时存在活动性HCC肿瘤与全口服DAA治疗失败显著相关。
  • HCC治愈性治疗后进行HCV治疗可获得极好的SVR。

研究设计与样本

  • 回顾性队列研究,纳入2014年1月至2015年11月在本机构接受DAA治疗的HCV阳性肝硬化患者,共421例。

主要发现

  • 421例HCV阳性肝硬化患者中,33%有活动性或既往HCC。
  • HCC患者未获得SVR的比例为21%,无HCC患者为12%(p=0.009)。
  • 29例未获得SVR的HCC患者中,27例(93%)发生在存在活动性肿瘤时。
  • 存在非活动性肿瘤或肿瘤切除/移植后接受DAA治疗可获得与无HCC患者相似的极好SVR率(p<0.0001)。
  • 多变量分析中,DAA治疗失败的主要预测因素是HCV治疗开始时存在活动性HCC(调整OR=8.5,95%CI=3.90-18.49)。

临床怎么用

  • 作者指出,HCV治疗开始时存在活动性HCC肿瘤与全口服DAA治疗失败显著相关;HCC治愈性治疗后进行HCV治疗可获得极好的SVR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The approval of all-oral direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) has led to the expansion of therapy to include patients with cirrhosis who have hepatocellular carcinoma (HCC). Data on the use of DAAs in HCV+ patients with HCC is limited. The aim of this study was to assess the efficacy of all-oral-DAA regimens in HCV+ cirrhotic patients who have or had HCC compared to those without HCC. METHODS: A retrospective cohort study was conducted on all cirrhotic patients who were treated for HCV with DAAs at our institution between January 2014 and November 2015. RESULTS: A total of 421 HCV+ patients with cirrhosis were identified, of whom 33% had active or a history of HCC. Failure to achieve sustained virologic response (SVR) occurred in 21% of patients with HCC compared to 12% of patients without HCC (p=0.009). Of the 29 patients with HCC who did not achieve SVR, 27 (93%) occurred when an active tumor was present. DAA therapy in the presence of an inactive tumor or after removal of tumor (resection/transplant) resulted in excellent SVR rates, similar to those without HCC (p<0.0001). In multivariable analysis, the primary predictor of DAA treatment failure was the presence of active HCC at the time of HCV treatment initiation (adjusted odds ratio=8.5, 95% confidence interval=3.90-18.49). CONCLUSIONS: The presence of active HCC tumor at the initiation of HCV therapy is significantly associated with all-oral DAA treatment failure. HCV treatment after curative therapies for HCC resulted in excellent SVR. LAY SUMMARY: The new medications for hepatitis C have excellent cure rates. However, our study shows that in patients with both liver cancer and hepatitis C, they do not achieve these cure rates. Patients with liver cancer are almost 8 times more likely to fail hepatitis C treatment than patients without liver cancer.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Prenner SB, VanWagner LB, Flamm SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017. PMID: 28161470. doi:10.1016/j.jhep.2017.01.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。